INTRODUCTION: Turner syndrome (TS) affects about one in 1,500 to 2,500 live-born females. Short stature is the most common physical abnormality in Turner syndrome, with adult stature average 20 cm shorter compared to the general population. Randomized, placebo-controlled studies to final adult height have proven that GH therapy is effective in increasing stature in Turner syndrome.

AIME: To study the efficiency of early initiation for GH therapy on final stature for patients with Turner syndrome and to prove its important role in obtaining optimal growth rates.

METHODS: We studied a lot of 24 patients with Turner syndrome diagnosed and followed up in our Department of Endocrinology. They were referred to our department for various reasons:

Turner’s syndrome may be associated with cardiovascular, skeletal, renal, thyroid, cognitive and reproductive disorders and diabetes type II. The most frequently congenital malformations associated with Turner syndrome were: congenital heart disease (7 cases), hypothyroidism (5 cases) and structural malformations of the kidneys (5 cases).

Considering the diagnosis age for Turner syndrome, 4 categories were defined:

1) 0-5 years (5%- 2 patients)
2) 5-10 years (36%- 8 patients)
3) 10-15 years (36%- 8 patients)
4) 15-20 years (23%- 6 patients)

Recombinant GH therapy was initiated for the last 3 categories.

RESULTS: The growth rate were significant in the 3 groups:

1) age 5-10 years: - average initial stature: 113,3 cm - follow up: 18 months - average growth rate: 0,736 cm/year - mean total height gain: 11,7 cm
2) age 10-15 years: - average initial stature: 124,6 cm - follow up: 24 months - average growth rate: 0,561 cm/year - mean total height gain: 15,0 cm
3) age 15-20 years: - average initial stature: 137,6 cm - follow up: 18 month - average growth: 0,278 cm/year - mean total height gain: 4,6 cm

CONCLUSION: Comparing the growth curves and the growth velocity in the 3 groups we noticed that growth rate decreased with late therapy initiation, which becomes an important factor for the final stature prognosis. Longer follow-up is important for evaluating the efficiency of early initiated GH therapy.

DISCUSSION: In patients group of 15-20 years we obtained the lowest growth rate, the incriminated factor being the associated substitutive oestrogen therapy and its effects on the bone plate. Estrogen therapy increases IGFBP-1, which will tend to lower free IGF-I. IGFBP-1 in itself is considered to be an inhibitory IGF binding protein.

REFERENCES:
1) Davenport ML. Source Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7032, USA; Recombinant growth hormone in children and adolescents with Turner syndrome. Cave CB, Bryant J, Milne R.
2) Wessex Institute for Health Research and Development, University of Southampton, Bassett Crescent East, Mailpoint 728, Biomedical Sciences Building, Southampton, UK, SO16 7PX.
4) Epidemiological, endocrine and metabolic features in Turner syndrome. Claus Højbjerg Gravholt Medical Department M (Endocrinology and Diabetes) and Medical Research Laboratories, Aarhus Sygehus, Aarhus University Hospital, DK-8000 Aarhus C, Denmark.